MYRIAD GENETICS, INC.

NASDAQ: MYGN

▲

28.52

+0.02

+0.07%

Currency In USD 9/17/2019 5:18 PM EDT

1 Day

Open

28.34
Previous Close

28.50
Volume (Avg)

802.79k (1.50M)
Day's Range

28.07-28.82
52Wk Range

22.04-48.77
Market Cap.

2.11B
Dividend Rate ( Yield)

-
Beta

0.96
Shares Outstanding

73.87M
P/E Ratio (EPS)

472.42 (0.06)

AdChoices

Top Stories

Here's Why Myriad Genetics Dropped 19.2% in August
The Motley Fool 9/8/2019
3 Cancer Treatment Stocks to Buy Right Now
The Motley Fool
33 Healthcare Stocks Moving In Monday's Pre-Market Session
Benzinga
Barron's Picks And Pans: American Eagle Outfitters, Chevron, Grocery Outlet And More
Benzinga
Myriad Genetics Limps Into Fiscal 2020
The Motley Fool 8/15/2019
61 Biggest Movers From Yesterday
Benzinga
Why Myriad Genetics, Nordstrom, and Luckin Coffee Slumped Today
The Motley Fool
Mid-Afternoon Market Update: Dow Falls Over 700 Points; Myriad Genetics Shares Plummet
Benzinga
Here's Why Myriad Genetics Is Getting Crushed Today
The Motley Fool
48 Stocks Moving In Wednesday's Mid-Day Session
Benzinga
Mid-Day Market Update: Crude Oil Down Over 5%; Purple Innovation Shares Rises After Q2 Results
Benzinga
Mid-Morning Market Update: Markets Open Lower; Macy's Misses Q2 Estimates
Benzinga
Benzinga's Top Upgrades, Downgrades For August 14, 2019
Benzinga
Myriad Genetics Sinks on Fourth-Quarter Earnings and Revenue Miss
The Street
32 Healthcare Stocks Moving In Wednesday's Pre-Market Session
Benzinga 8/14/2019

Gainers Akari Therapeutics, Inc. (NASDAQ: AKTX) shares rose 43.6% to $2.60 during Wednesday's pre-market session. The market cap stands at $28.6 million. Guardion Health Sciences, Inc. (NASDAQ: GHSI) shares surged 17.9% to $0.28. The market value of their outstanding shares is at $28.3 million. Kitov Pharma, Inc. (NASDAQ: KTOV) shares increased by 16.5% to $0.92. The market cap stands at $28.5 million. InMode, Inc. (NASDAQ: INMD) shares moved...
31 Stocks Moving In Wednesday's Pre-Market Session
Benzinga
The Daily Biotech Pulse: Regeneron's Bad Cholesterol Drug Aces Late-Stage Trial, Oncolytics Offering
Benzinga
A Peek Into The Markets: US Stock Futures Signal Lower Start On Wall Street
Benzinga

MYRIAD GENETICS, INC.

Top Stories

Here's Why Myriad Genetics Dropped 19.2% in August

3 Cancer Treatment Stocks to Buy Right Now

33 Healthcare Stocks Moving In Monday's Pre-Market Session

Barron's Picks And Pans: American Eagle Outfitters, Chevron, Grocery Outlet And More

Myriad Genetics Limps Into Fiscal 2020

61 Biggest Movers From Yesterday

Why Myriad Genetics, Nordstrom, and Luckin Coffee Slumped Today

Mid-Afternoon Market Update: Dow Falls Over 700 Points; Myriad Genetics Shares Plummet

Here's Why Myriad Genetics Is Getting Crushed Today

48 Stocks Moving In Wednesday's Mid-Day Session

Mid-Day Market Update: Crude Oil Down Over 5%; Purple Innovation Shares Rises After Q2 Results

Mid-Morning Market Update: Markets Open Lower; Macy's Misses Q2 Estimates

Benzinga's Top Upgrades, Downgrades For August 14, 2019

Myriad Genetics Sinks on Fourth-Quarter Earnings and Revenue Miss

32 Healthcare Stocks Moving In Wednesday's Pre-Market Session

31 Stocks Moving In Wednesday's Pre-Market Session

The Daily Biotech Pulse: Regeneron's Bad Cholesterol Drug Aces Late-Stage Trial, Oncolytics Offering

A Peek Into The Markets: US Stock Futures Signal Lower Start On Wall Street